Dissecting the molecular mechanisms of breast cancer bone metastasis for therapeutic targeting

dc.contributorInstitute of Biomedicine.-
dc.contributor.authorPollari, Sirkku
dc.contributor.departmentfi=Biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.facultyfi=Lääketieteellinen tiedekunta|en=Faculty of Medicine|
dc.date.accessioned2012-03-29T09:49:23Z
dc.date.available2012-03-29T09:49:23Z
dc.date.issued2012-04-14
dc.description.abstractBreast cancer that has metastasized to bone is currently an incurable disease, causing significant morbidity and mortality. The aim of this thesis work was to elucidate molecular mechanisms of bone metastasis and thereby gain insights into novel therapeutic approaches. First, we found that L‐serine biosynthesis genes, phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase 1 (PSAT1) and phosphoserine phosphatase (PSPH), were up‐regulated in highly bone metastatic MDA‐MB‐231(SA) cells as compared with the parental breast cancer cell line. Knockdown of serine biosynthesis inhibited proliferation of MDA‐MB‐231(SA) cells, and L‐serine was essential for the formation of bone resorbing osteoclasts. Clinical data demonstrated that high expression of PHGDH and PSAT1 was associated with decreased relapse‐free and overall survival and with features typical of poor outcome in breast cancer. Second, RNA interference screening pointed out heparan sulfate 6‐O‐sulfotransferase 2 (HS6ST2) as a critical gene for transforming growth factor β (TGF‐β)‐induced interleukin 11 (IL‐11) production in MDA‐MB‐231(SA) cells. Exogenous heparan sulfate glycosaminoglycans heparin and K5‐NSOS also inhibited TGF‐β‐induced IL‐11 production in MDA‐MB‐231(SA) cells. Furthermore, K5‐NSOS decreased osteolytic lesion area and tumor burden in bone in mice. Third, we discovered that the microRNAs miR‐204, ‐211 and ‐379 inhibited IL‐11 expression in MDA‐MB‐231(SA) cells through direct targeting of the IL‐11 mRNA. MiR‐379 also inhibited Smad‐mediated signaling. Gene expression profiling of miR‐204 and ‐379 transfected cells indicated that these microRNAs down‐regulate several bone metastasis‐relevant genes, including prostaglandin‐endoperoxide synthase 2 (PTGS2). Taken together, this study identified three potential treatment strategies for bone metastatic breast cancer: inhibition of serine biosynthesis, heparan sulfate glycosaminoglycans and restoration of miR‐204/‐211/‐379.-
dc.description.accessibilityfeatureei tietoa saavutettavuudesta
dc.description.notificationSiirretty Doriasta
dc.format.contentfulltext
dc.identifierISBN 978-951-29-4962-5-
dc.identifier.olddbid79293
dc.identifier.oldhandle10024/74821
dc.identifier.urihttps://www.utupub.fi/handle/11111/27293
dc.identifier.urnURN:ISBN:978‐951‐29‐4962‐5
dc.language.isoeng-
dc.publisherAnnales Universitatis Turkuensis D 1008-
dc.publisherfi=Turun yliopisto|en=University of Turku|en
dc.relation.ispartofseriesTurun yliopiston julkaisuja. Sarja D, Medica – Odontologica
dc.relation.issn2343-3213
dc.relation.numberinseries1008-
dc.source.identifierhttps://www.utupub.fi/handle/10024/74821
dc.titleDissecting the molecular mechanisms of breast cancer bone metastasis for therapeutic targeting-
dc.type.ontasotfi=Artikkeliväitöskirja|en=Doctoral dissertation (article-based)|

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
AnnalesD1008Pollari.pdf
Size:
3.92 MB
Format:
Adobe Portable Document Format